REG - Craven House Capital - Investee company update: Bio Vitos

Craven House CapitalAnnouncement

03/07/2023 13:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230703:nRSC7870Ea&default-theme=true

RNS Number : 7870E  Craven House Capital PLC  03 July 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION
(EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE
OF THE EU (WITHDRAWAL) ACT 2018.

Craven House Capital plc

("Craven House" or the "Company")

Investee company update: Bio Vitos

The Board of Craven House notes the announcement released earlier today by
Hemcheck Sweden AB ("Hemcheck").  Further to its investee company update
released at 7:00AM on 8 February 2023, which outlined that its investee
company Bio Vitos was being acquired in a share exchange transaction by Nasdaq
listed Hemcheck, Craven House now announces that whilst the acquisition by
Hemcheck has now been completed and approved by Hemcheck shareholders, the
prior approval application submitted to Nasdaq Stockholm, by Hemcheck, has not
been approved by Nasdaq. Hemcheck and Bio Vitos have therefore entered into a
supplementary agreement that will enable current operations to remain in
operation whilst an updated re-listing application is submitted by Hemcheck to
Nasdaq.

Bio Vitos anticipates that it will receive its shares in Hemcheck before the
end of July 2023 which will be passed directly onto the Bio Vitos
shareholders, which include Craven House. Craven House's 24.5% holding in Bio
Vitos, will remain unchanged.

Further announcements will be made in due course as appropriate.

 

For further information please contact:

 Craven House Capital Plc                                                Tel: 0203 286 8130

 Mark Pajak

 www.Cravenhousecapital.com (http://www.cravenhousecapital.com/)

 SI Capital                                                              Tel: 01483 413500

 Broker

 Nick Emerson

 www.sicapital.co.uk (http://www.sicapital.co.uk/)

 SPARK Advisory Partners Limited                                         Tel: 0203 368 3550

 Nominated Adviser

 Matt Davis/James Keeshan

 www.Sparkadvisorypartners.com (http://www.sparkadvisorypartners.com/)

About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a
portfolio of companies, partnerships, joint ventures, businesses or other
assets participating in the e-Commerce sector.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFFFDAIVIIV